A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the long-term safety of CAM2029 in patients with
acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12
months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label
treatment week 24-52 in this trial.